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Abstract: Veratrum californicum is a rich source of steroidal alkaloids such as cyclopamine, a known
inhibitor of the Hedgehog (Hh) signaling pathway. Here we provide a detailed analysis of the alkaloid
composition of V. californicum by plant part through quantitative analysis of cyclopamine, veratramine,
muldamine and isorubijervine in the leaf, stem and root/rhizome of the plant. To determine whether
additional alkaloids in the extracts contribute to Hh signaling inhibition, the concentrations of these
four alkaloids present in extracts were replicated using commercially available standards, followed by
comparison of extracts to alkaloid standard mixtures for inhibition of Hh signaling using Shh-Light II
cells. Alkaloid combinations enhanced Hh signaling pathway antagonism compared to cyclopamine
alone, and significant differences were observed in the Hh pathway inhibition between the stem and
root/rhizome extracts and their corresponding alkaloid standard mixtures, indicating that additional
alkaloids present in these extracts are capable of inhibiting Hh signaling.
Keywords: hedgehog signaling; Veratrum californicum; cyclopamine; HPLC-MS; Shh-Light II cells

1. Introduction
The Hedgehog (Hh) signaling pathway plays a vital role in embryonic development [1,2].
In mammals, the Hh signaling pathway consists of the secreted ligands Sonic hedgehog (Shh), Desert
hedgehog (Dhh) and Indian hedgehog (Ihh); the transmembrane receptor proteins Patched (Ptch1 and
Ptch2), the transmembrane signal transducer Smoothened (Smo), and the Gli transcription factors
(Gli1, Gli2, Gli3) [3]. In the absence of Hh ligands, Ptch1 prevents the translocation of Smo to the
primary cilia, thereby inhibiting the nuclear localization of Gli and suppressing transcriptional activity.
Upon binding of Hh ligands to Ptch1, Smo suppression is abolished and downstream pathway activity
proceeds, resulting in nuclear translocation and activation of Gli. Although the Hh ligand proteins
all act as morphogens and have similar physiological effects, each Hh ligand performs specialized
functions due to the spatial and temporal differences in their expression [4]. The Shh signaling
pathway is a major regulator of various processes, including cell differentiation and proliferation,
and tissue polarity [2,5]. Inhibition of Shh signaling is widely researched because aberrant Shh
signaling is a hallmark of many cancers [6–8], including prostate, gallbladder, pancreatic, and basal
cell carcinoma [9–12]. Basal cell carcinoma (BCC) is the most common human cancer and is driven
predominantly by the hyperactivation of the Hh pathway [13–15]. For this reason, a significant number
of BCC patients experience a clinical benefit from vismodegib (Erivedge® ), a Smo inhibitor approved
by the US Food and Drug Administration (FDA) to treat metastatic or reoccurring BCC [16]. In phase 2
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trials in BCC patients, a majority experienced clinical benefit with vismodegib treatment that included
30% of metastatic BCC patients demonstrating a 30% decrease in visible tumor dimension, and 64%
experiencing stable tumor size. In patients with locally advanced BCC, 43% showed a 30% decrease
in visible tumor dimension, and 38% demonstrating stable tumor size. However, development
of resistance to vismodegib in up to 20% of advanced BCC patients within one year of treatment
represents a significant limitation [15,17]. Various studies have implicated amino acid mutations in
the vismodegib binding-site in Smo as a mechanism underlying acquired resistance [15,18,19]. Due to
adverse side effects and the potential for acquired resistance to vismodegib there is a continued need
to investigate novel compounds that target the Hh signaling pathway, and identification of natural
products that act as Hh signaling inhibitors continues to be investigated [20–23].
Veratrum californicum (V. californicum) is native to the western United States and is rich in steroidal
alkaloids, including cyclopamine, veratramine, isorubijervine and muldamine [6,24]. Of these alkaloids,
the most notorious is cyclopamine, a teratogen antagonist of the Shh signaling pathway [25]. Interest in
V. californicum arose in the 1950s when unsettling high incidences of craniofacial birth defects in
lambs were observed by shepherds in Idaho. Numerous review articles have recounted the history
of scientific interest in V. californicum, the efforts undertaken by researchers at the Poisonous Plant
Research Laboratory in Logan, UT to identify and validate the causative agents of the observed
birth defects, and the chronological order of the isolation and structural elucidation of individual
steroidal alkaloids [6,26,27]. However, few reports in the literature have used modern, highly sensitive
analytical techniques to examine the full array of steroidal alkaloids in V. californicum [28]. Our lab
has implemented extraction techniques of the root and rhizome of V. californicum aimed at isolating
these steroidal alkaloids and characterizing their bioactivity towards Hh signaling using Shh-Light
II cell assays [28,29]. In the current study, we used ethanol extraction of the leaves, stems and
roots of V. californicum to determine if alkaloid ratios in the extract yield synergistic amplification of
Hh signaling suppression as compared to traditional single alkaloid activity. The extracts were
characterized using liquid chromatography and high resolution electrospray ionization time of
flight tandem mass spectrometry, and their biological activity was tested using Shh-Light II cells.
The concentrations of cyclopamine, veratramine, isorubijervine and muldamine were determined,
and mixtures of commercially available standards were prepared in the same ratios as found in the
extracts derived from the leaf, stem and root/rhizome of V. californicum. We sought to test whether
well-characterized steroidal alkaloids, at ratios consistent with native plant content, exhibited a
synergistic effect to inhibit Hh pathway signaling commensurate with plant extract. Additionally,
we sought to determine if additional alkaloids present in the V. californicum contribute to Hh
signaling inhibition. Earlier investigations of V. californicum alkaloids may have failed to identify
less abundant alkaloids that are biologically significant and potentially valuable novel Hh pathway
signaling antagonists.
2. Results
2.1. Qualitative Comparison of V. californicum Alkaloids by Plant Part
Qualitative variation is observed in the alkaloid composition of V. californicum by plant part.
The alkaloid profiles of the extracts from the leaf, stem and root/rhizome of V. californicum are shown
in Figure 1a–c. Identification of each alkaloid peak was achieved by high resolution mass spectrometry
and verified by elution time compared to commercially available standards. Data for the most
prominent peaks labelled in Figure 1a–c including retention time, m/z, molecular formula (MF) and
alkaloid identity are summarized in Table 1. Mass spectra showing the m/z for each alkaloid used to
estimate molecular formulas listed in Table 1 are shown in Supplemental Figure S1.
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Figure 1. Alkaloid chromatograms for biomass extracts from the (a) leaf, (b) stem, and (c)
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Cyclopamine (Peak 10, m/z 412.3186) and veratramine (Peak 9, m/z 410.3023) were observed
in each of the three plant part extracts. Alkaloids present in both the stem and leaf extracts include
cycloposine (Peak 3, m/z 574.3699) and veratrosine (Peak 4, m/z 572.3530), which are glycosylated
cyclopamine and veratramine, respectively. Peak 1 is a glycosylated alkaloid observed only in stem
extract, with an m/z of 576.3836, corresponding to molecular formula C33 H53 NO7 . In the stem and
root/rhizome extracts, isorubijervine (Peak 12, m/z 414.3342) and muldamine (Peak 13, m/z 458.3587)
are both observed.
Peaks 4, 5, 6, 14 and 15 in Figure 1c correspond to unique alkaloids present only in the
root/rhizome extract. These alkaloids have m/z of 414.3337, 430.3282, 428.3136, 400.3550 and
456.3446 and correspond to the estimated molecular formulas of C27 H43 NO2 , C27 H43 NO3 , C27 H41 NO3 ,
C27 H45 NO and C29 H45 NO3 , respectively. Potential cyclopamine isomers were observed in the root
extract, with a m/z consistent with cyclopamine observed to elute with three distinct retention times.
Figure 1g shows the extracted ion chromatogram (EIC) for cyclopamine generated using the m/z
window 412.3186 ± 0.02, and the corresponding mass spectra are shown in Figure 1h–j. Figure 1d
shows the EIC for veratramine using the m/z window 410.3023 ± 0.01, and the corresponding mass
spectra are shown in Figure 1e,f.
2.2. Quantitative Analysis of V. californicum Alkaloids
Quantification of cyclopamine, veratramine, isorubijervine and muldamine in alkaloid extracts
were determined using charged aerosol detection and calibration curves generated from commercially
available standards, with values of R2 greater than 0.99. Extractions were preformed three times,
and alkaloid concentrations are shown by plant part in Table 2 as mg of each alkaloid extracted per
g of initial biomass ± the standard deviation of the concentration observed in triplicate quantities.
The quantity of cyclopamine was determined to be 0.21 ± 0.02 mg/g, 3.23 ± 0.16 mg/g, and 7.38 ±
0.08 mg/g for the leaf, stem and root/rhizome, respectively.
Table 2. Quantification of cyclopamine, veratramine, muldamine and isorubijervine by plant part.
Alkaloid quantities are reported as mg of alkaloid per g of plant biomass.
Plant Part

Cyclopamine

Veratramine

Muldamine

Isorubijervine

Leaf
Stem
Root/Rhizome

0.21 ± 0.02
3.23 ± 0.16
7.38 ± 0.08

0.09 ± 0.01
1.33 ± 0.13
3.07 ± 0.14

Not Detected
0.36 ± 0.06
3.47 ± 0.23

Not Detected
1.00 ± 0.08
2.92 ± 0.09

2.3. Bioactivity Evaluation of Combined Standards and Plant Extracts
Alkaloid standard mixtures were created using commercially available standards in the same
ratios as observed in the three plant parts. HPLC was used to validate that the alkaloid standard
mixtures matched the concentrations of the ethanolic extract, as is shown for the root/rhizome
extract and root standard mixture in Supplemental Figure S2. The bioactivity of these alkaloid
standard mixtures were quantified using Shh-Light II cells, and compared to cyclopamine alone at
the same concentration, and to V. californicum extracts derived from leaf, stem, and root/rhizome
of the plant. The treatment conditions evaluating Hh signaling inhibition in Shh-Light II cells are
summarized in Supplemental Table S1 with extracts and alkaloid standard mixtures normalized
to cyclopamine concentrations of 0.5 and 0.1 µM, referred to as “high concentration” and “low
concentration” treatments herein. The results of the biological assays are shown in Figure 2. There is
no significant difference between cyclopamine, the alkaloid standard mixtures, and the plant extracts
at high concentration treatments shown in Figure 2a. In the low concentration treatments shown in
Figure 2b, there is no significant difference observed between cyclopamine standard, and the leaf
standard mixture or the leaf extract, indicating that the addition of 0.04 µM veratramine in the standard
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Peak 4, observed solely in the root/rhizome extract has an m/z and predicted molecular formula
consistent with etioline. In this study, potential cyclopamine isomers (see Figure 1g) were observed
in the root/rhizome extract analyzed by LC-MS. One of these potential cyclopamine isomers may
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be dihydroveratramine, which has previously been identified in Veratrum album by Wilson, et al. [31].
However, the relative retention time between dihydroveratramine and cyclopamine, observed
by Wilson, et al., does not support this conclusion, because dihydroveratramine (RT: 13.66 min)
was observed to elute prior to cyclopamine (RT: 15.09 min), whereas the purported cyclopamine
isomer observed in this study elutes after cyclopamine (see Table 1) under similar HPLC conditions.
No naturally occurring isomers of cyclopamine have been previously observed in V. californicum.
In Shh-Light II cells using the Dual-Glo® Luciferase Assay System, we evaluated the inhibition of
Hh signaling of cyclopamine alone, combinations of alkaloid standards, and the inhibitory potential
of extracts from each plant part. As shown in Figure 2a, there is no significant difference between
cyclopamine, the alkaloid standard mixtures, and the plant extracts at high concentration treatments.
There are trends that indicate enhanced inhibition of alkaloid standard mixtures and extracts compared
to cyclopamine alone, but these do not amount to statistically significant differences. The reason for
this result may be due to low levels of Gli reporter activity observed in each treatment. However, as
demonstrated in Figure 2b, it was determined that addition of 0.1 µM muldamine, veratramine and
isorubijervine enhance Hh signaling inhibition significantly when compared to cyclopamine alone,
as demonstrated by the stem and root/rhizome standard mixtures compared to cyclopamine alone.
Addition of veratramine to cyclopamine does not enhance Hh signaling inhibition as demonstrated by
the leaf standard mixture compared to solely cyclopamine. By replicating concentrations of cyclopamine,
veratramine, isorubijervine and muldamine observed in plant extracts using commercially available
standards and comparing the inhibitory potential of the plant extracts to alkaloid standard mixtures,
we determined that additional alkaloids present in the crude stem and root/rhizome extracts inhibit
Hh signaling. The alkaloids present in the leaf extract include cycloposine, veratrosine, cyclopamine,
veratramine, and the potential veratramine isomer labeled Peak 8 in Figure 1. No difference is observed
between the leaf extract at low concentration and the corresponding combined standard mixture.
This result indicates that cycloposine, veratrosine and Peak 8 do not contribute to Hh signaling inhibition
in this model system. However, it has been proposed that hydrolysis of the glycosidic linkage in
glycosylated alkaloids during digestion contributed to the teratogenic effects of V. californicum alkaloids
when consumed by foraging sheep [32]. Furthermore, no significant difference is observed between
cyclopamine alone, the leaf standard mixture or the leaf extract, indicating that the addition of 0.04 µM
veratramine in the standard mixture, or the additional alkaloids present in the leaf extract did not
enhance Hh signaling inhibition. We observed a significant difference between the alkaloid standard
mixtures of the stem and root/rhizome samples and cyclopamine alone. This indicates the addition of
veratramine, isorubijervine and muldamine enhance Hh inhibition. However, the modest enhancement
of Hh inhibition seems to be additive rather than synergistic, with the addition of these alkaloids
providing additional, albeit more weakly inhibitory compounds. No Hh inhibition was demonstrated
for 0.2 µM veratramine in the leaf standard minus cyclopamine treatment, indicating veratramine does
not inhibit the Hh signaling pathway. This corroborates feeding trials in which veratramine was shown
to cause teratogenic malformations in sheep distinct from cyclopia, such as hypermobility of the knee
joints leading to bow-legged lambs unable to stand [33]. The stem and root/rhizome standard mixtures
containing veratramine, isorubijervine and muldamine indicate that muldamine and/or isorubijervine
inhibit the Hh pathway. Muldamine has been shown to result in craniofacial defects in hamsters in
feeding studies that may be attributed to interruption of normal Hh signaling [34]. Further investigation
to isolate, characterize, and assess the bioactivity of individual, less abundant alkaloids present in the
stem and root/rhizome extracts is underway.
4. Materials and Methods
4.1. Chemicals and Solvents
Cyclopamine (>99% purity) was purchased from Alfa Aesar (Ward Hill, MA, USA), veratramine
(>98% purity) was purchased from Abcam Biotechnology Company (Cambridge, UK), and
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isorubijervine (99% purity) and muldamine (99% purity) were purchased from Logan Natural Products
(Plano, TX, USA). The purity of the reference standards was verified in house by HPLC-MS. Extraction
and purification solvents, 95% ethanol, ammonium hydroxide and chloroform were purchased from
Fisher Scientific (Pittsburgh, PA, USA). High pressure liquid chromatography (HPLC) mobile phases
included 0.1% formic acid and HPLC grade acetonitrile (>99% purity, Fisher Scientific).
4.2. Sample Extraction and Preparation
A complete specimen of V. californicum was harvested in the Boise National Forest, Idaho at an
elevation of 2134 m. The leaf, stem and roots/rhizomes of the plant were separated, and all plant
parts were cut into smaller pieces to fit into quart size sealable bags. The specimens were placed in a
cooler on a bed of ice for transportation. The biomass was collected at a late stage in the plant’s life
cycle; the plant had noticeable brown edges along its leaves and top indicating annual deterioration
of above ground material in preparation for winter. Within two hours and upon arrival in the lab,
the plant material was chopped into 2 cm segments and dried for 14 h using a LabConco Freezone
4.5 freeze drying unit (Labconco Corporation, Kansas City, MO, USA), followed by storage at −20 ◦ C.
The biomass was flash frozen in liquid nitrogen, and pulverized into a fine powder using a mortar and
pestle. Approximately 2.0 g of powdered biomass was added to a 250 mL round bottom flask followed
by 100 mL of 95% ethanol. The resultant slurry was sonicated for 1 h and then agitated for 24 h on
a stir plate. The biomass was removed by vacuum filtration (Whatman filter paper, 0.45 µm), and
solvent removed by rotary evaporation. The dried crude extract was dissolved in 10 mL of ethanol,
and the solution was warmed to 40 ◦ C and sonicated to achieve complete dissolution. Addition of 35%
aqueous ammonia achieved alkaline solvent conditions (pH ≥ 10). The aqueous alkaline solution was
added directly to a supported liquid extraction (SLE) column (Chem Elut, Agilent, Santa Clara, CA,
USA) and allowed to adsorb for 10 min, followed by elution of alkaloids with chloroform (3 × 10 mL)
using a vacuum manifold set to a pressure of 2 mbar. The chloroform fractions were combined, filtered,
and evaporated to dryness. All samples were dissolved in 1 mL ethanol as a mixture of alkaloids.
4.3. Alkaloid Quantification
The concentrations of cyclopamine, veratramine, isorubijervine and muldamine in alkaloid
extracts were determined using an UltiMate 3000 HPLC (Thermo Scientific, Waltham, MA, USA)
equipped with a Corona Veo RS charge aerosol detector (CAD) and MSQ Plus mass spectrometer (MS).
HPLC separation of alkaloids was achieved using a Thermo Acclaim 120 C18 column (2.1 × 150 mm,
3 µm), and mobile phases consisting of 0.1% formic acid (v/v) in water (Buffer A) and 0.1% formic acid
(v/v) in acetonitrile (Buffer B) with a flow rate of 0.3 mL/min. A linear gradient method beginning at
95% Buffer A and 5% Buffer B, up to 60% Buffer B over a 25 min run time achieved desired separation
of alkaloids from the extracts. Cyclopamine, veratramine, isorubijervine and muldamine standards
were used to create a calibration curve at concentrations of 0.1, 0.5, 1.0, 5.0 and 10.0 mM with detection
recorded by a CAD with the power function set to pA 1.70. Calibration curves were generated in
triplicate for each alkaloid at each of the five alkaloid concentrations. The quantity of these alkaloids
were determined from the alkaloid mixtures obtained from the leaf, stem and root extracts in triplicate.
4.4. Alkaloid Identification
In order to identify the steroidal alkaloids in V. californicum leaf, stem and root/rhizome extracts,
samples were analyzed by HPLC-MS, where the mass spectrometer was an ultra-high resolution
Quadrupole Time of Flight (QTOF) instrument (Bruker maXis, Billerica, MA, USA). The electrospray
ionization (ESI) source was operated under the following conditions: positive ion mode, 1.2 bar
nebulizer pressure, 8 L/min flow of N2 drying gas heated to a temperature of 200 ◦ C, 3000 V to −500 V
voltage between HV capillary and HV end-plate offset, mass range set from 80 to 800 m/z, and the
quadrupole ion energy at 4.0 eV. Sodium formate was used to calibrate the system in this mass range
of 80 to 800 m/z. HPLC separation was achieved using a XTerra MS C18 column, 3.5 µm, 2.1 × 150 mm
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(Waters, Milford, MA, USA). The flow rate was 250 µL/min. The mobile phases were 5% acetonitrile
and 0.1% formic acid in water (Buffer A) and acetonitrile and 0.1% formic acid (Buffer B). The linear
gradient method was used to separate analytes starting at 5% Buffer B and increasing to 60% Buffer B
over 25 min. A 1 µL sample injection was used. Data were analyzed with the Compass Data Analysis
software package (Bruker Corporation).
4.5. Cell Culture
Shh-Light II cells (JHU-068) were maintained in Dulbecco’s Modified Eagle Medium (DMEM)
(Gibco, Carlsbad, CA, USA) supplemented with 0.4 mg/mL geneticin, 0.15 mg/mL Zeocin™
(Invitrogen, Carlsbad, CA, USA), and 10% bovine calf serum. The cells were grown at 37 ◦ C in
an atmosphere of 5% CO2 in air and 100% relative humidity. This mouse embryonal NIH 3T3 cell line
contains a stably transfected luciferase reporter with eight copies of the consensus Gli binding site [35].
Alkaloid treatment conditions were dissolved in ethanol and added to DMEM media containing 0.5%
bovine calf serum.
4.6. Biological Assays
Cell density was determined using Trypan Blue (Stemcell Technologies, Vancouver, BC, Canada)
and a hemocytometer. Shh-Light II cells were seeded in a 96-well plate with 10,000 cells per well, and
grown to complete confluence in the media described above. When cells were confluent, the media
was replaced with DMEM supplemented with 0.5% bovine calf serum, and treated with 0.1 ng of
N-terminal mouse recombinant Shh (R&D Systems, Minneapolis, MN, USA) dissolved in DMEM, and
select alkaloid treatment. In each experiment, the controls and treatment wells contained all vehicles,
with a final ethanol concentration of 0.05%. Gli activity in the Shh-Light II cell line was assayed 48 h
after treatment with Shh protein and select compounds using the Dual-Luciferase Reporter Assay
System (Promega, Madison, WI, USA). The Gli-activity was measured by luminescence emitted from
cells using a Synergy H1m Microplate reader (BioTek, Winooski, VT, USA). The Gli-activity determined
in the biological assay is presented as a relative response ratio (RRR) as described in the Dual-Luciferase
Reporter Assay System manual. Each experiment was performed three times.
Supplementary Materials: The following are available online; Supplementary S1–S2, Table S1.
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